Clinical Trials Logo

HR-positive Breast Cancer clinical trials

View clinical trials related to HR-positive Breast Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04448886 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Start date: September 23, 2020
Phase: Phase 2
Study type: Interventional

This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: - Sacituzumab govitecan (IMMU-132) - Pembrolizumab (Keytruda®; MK-3475)